Previous 10 | Next 10 |
Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference Canada NewsWire HAMILTON , ON and BOSTON, Jan. 21, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on devel...
Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals Canada NewsWire HAMILTON , ON and BOSTON , Jan. 11, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncolog...
Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development Canada NewsWire Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technolog...
Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference Canada NewsWire HAMILTON , Ontario and BOSTON, Nov. 11, 2021 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on ...
Fusion Pharmaceuticals (NASDAQ:FUSN): Q3 GAAP EPS of -$0.45. Cash, cash equivalents and investments of $238.2M Press Release For further details see: Fusion Pharmaceuticals reports Q3 results
Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update Canada NewsWire FPI-1434 Phase 1 multi-dose data now expected in 2H 2022 FPI-1966 Phase 1 study initiated; first patient expected to be dosed in Q1 2022 FP...
Fusion Pharmaceuticals (NASDAQ:FUSN) announced that the compensation committee of the company's board granted stock option awards to purchase 90.4K shares to one employee outside Fusion's 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to th...
Fusion Pharmaceuticals (NASDAQ:FUSN) announces the appointment of Christopher Leamon as the company's chief scientific officer. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals. He was most recently executive direc...
Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer Canada NewsWire - Eric Burak , Ph.D. Appointed as Chief Technology Officer HAMILTON , Ontario and BOSTON, Nov. 2, 2021 /CNW/ --...
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies PR Newswire Single and multiple doses of FPI-1966 demonstrated therapeutic efficacy in a preclinical bladder xenograft model [ ...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...